SCHEMBL5065441

SCHEMBL5065441

Cn1c(=O)c(-c2ccc(F)c(N)c2)cc2cnc(N)nc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.60
FGFR2 P21802 2/20 0.60
FGFR4 P22455 2/20 0.60
FGFR3 P22607 2/20 0.60
SRC P12931 3/20 0.57
EGFR P00533 2/20 0.57
BRAF P15056 1/20 0.52
BRD4 O60885 1/20 0.46
ABL1 P00519 2/20 0.44
WEE1 P30291 2/20 0.43
LCK P06239 1/20 0.41
KIT P10721 1/20 0.41
KDR P35968 1/20 0.41
ACVR1 Q04771 2/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
STAT5A P42229 1/20 0.41
PKMYT1 Q99640 1/20 0.41
RIPK2 O43353 2/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5065270 0.86 SRC (0.56) FGFR1SRCEGFRBRAFABL1
SCHEMBL4283199 0.86 FGFR1 (0.45) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL4283863 0.85 PIK3CA (0.48) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL4275931 0.85 BRAF (0.43) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL5062647 0.84 CYP1A2 (0.52) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL31338489 0.82 BRAF (0.64) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL26930657 0.82 BRAF (0.64) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL4551707 0.81 PIK3CA (0.48) CYP1A2CYP3A4
SCHEMBL2245255 0.81 FGFR1 (0.67) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL5057413 0.81 SRC (0.54) FGFR1FGFR2FGFR4FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 FGFR1 577/4885FGFR2 1106/4885FGFR4 1073/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR1 577/4885FGFR2 1106/4885FGFR4 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.